Artemisinin derivatives: Toxic for laboratory animals, safe for humans?

Toxicology Letters

Volumn 147, Issue 2, 2004, Pages 99-107

  Gordi, Toufigh ^a   Lepist, Eve Irene ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Arteether; Artemether; Artesunate; Pharmacokinetics; Toxicity

Indexed keywords

ANTIMALARIAL AGENT; ARTEETHER; ARTEMETHER; ARTEMISININ; ARTEMISININ DERIVATIVE; ARTESUNATE; DIHYDROARTEMISININ; SESQUITERPENE;

ALLERGIC REACTION; ALLERGIC URTICARIA; ANIMAL; CLINICAL TRIAL; DIARRHEA; DOG; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; HUMAN; MACACA; MALARIA; MOUSE; NAUSEA; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; SIDE EFFECT; SLOW DRUG RELEASE; SPECIES DIFFERENCE; VOMITING;

ANIMALIA;

EID: 1642482269     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2003.12.009     Document Type: Review

References (42)

1. Brewer T.G., Grate S.J., Peggins J.O., Weina P.J., Petras J.M., Levine B.S., Heiffer H.M., Schuster B.G. Fatal neurotoxicity of arteether and artemether. Am. J. Trop. Med. Hyg. 51:1994a;251-259.
2. Brewer T.G., Peggins J.O., Grate S.J., Petras J.M., Levine B.S., Weina P., Swearengen J.J., Heiffer M.H., Schuster B.G. Neurotoxicity in animals due to arteether and artemether. Trans. R. Soc. Trop. Med. Hyg. 88(Suppl. 1):1994;33-36.
3. Brewer T.G., Genovese R.F., Newman D.B., Li Q. Factors relating to neurotoxicity of artemisinin antimalarial drugs "listening to arteether" Med. Trop. (Mars.). 58(Suppl. 3):1998;22-27.
4. Davis T.M., Edwards G.O., McCarthy J.S. Artesunate and cerebellar dysfunction in falciparum malaria. N. Engl. J. Med. 337:1997;792.
5. Davis T.M., Binh T.Q., Ilett K.F., Batty K.T., Phuong H.L., Chiswell G.M., Phuong V.D., Agus C. Penetration of dihydroartemisinin into cerebrospinal fluid after administration of intravenous artesunate in severe falciparum malaria. Antimicrob. Agents Chemother. 47:2003;368-370.
6. Elias Z., Bonnet E., Marchou B., Massip P. Neurotoxicity of artemisinin: possible counseling and treatment of side effects. Clin. Infect. Dis. 28:1999;1330-1331.
7. Gabriels M., Plaizier-Vercammen J.A. Physical and chemical evaluation of liposomes, containing artesunate. J. Pharm. Biomed. Anal. 31:2003;655-667.
8. Genovese R.F., Newman D.B., Gordon K.A., Brewer T.G. Acute high dose arteether toxicity in rats. Neurotoxicology. 20:1999;851-859.
9. Genovese R.F., Newman D.B., Brewer T.G. Behavioral and neural toxicity of the artemisinin antimalarial, arteether, but not artesunate and artelinate, in rats. Pharmacol. Biochem. Behav. 67:2000;37-44.
10. Genovese R.F., Nguyen H.A., Mog S.R. Effects of arteether on an auditory radial-arm maze task in rats. Physiol. Behav. 73:2001;87-91.
11. Hien T.T. An overview of the clinical use of artemisinin and its derivatives in the treatment of falciparum malaria in Vietnam. Trans. R. Soc. Trop. Med. Hyg. 88(Suppl. 1):1994;7-8.
12. Hien T.T., Turner G.D., Mai N.T., Phu N.H., Bethell D., Blakemore W.F., Cavanagh J.B., Dayan A., Medana I., Weller R.O., Day N.P., White N.J. Neuropathological assessment of artemether-treated severe malaria. Lancet. 362(9380):2003;295-296.
13. Jung M., Lee K., Kendrick H., Robinson B.L., Croft S.L. Synthesis, stability, and antimalarial activity of new hydrolytically stable and water-soluble (+)-deoxoartelinic acid. J. Med. Chem. 45:2002;4940-4944.
14. Kissinger E., Hien T.T., Hung N.T., Nam N.D., Tuyen N.L., Dinh B.V., Mann C., Phu N.H., Loc P.P., Simpson J.A., White N.J., Farrar J.J. Clinical and neurophysiological study of the effects of multiple doses of artemisinin on brain-stem function in Vietnamese patients. Am. J. Trop. Med. Hyg. 63:2000;48-55.
15. Le N.H., Na-Bangchang K., Le T.D., Thrinh K.A., Karbwang J. Pharmacokinetics of a single oral dose of dihydroartemisinin in Vietnamese healthy volunteers. SE Asia J. Trop. Med. Public Health. 30:1999;11-16.
16. Leonardi E., Gilvary G., White N.J., Nosten F. Severe allergic reactions to oral artesunate: a report of two cases. Trans. R. Soc. Trop. Med. Hyg. 95:2001;182-183.
17. Li Q.G., Guo X.B., Fu L.C., Jian X.H., Wang X.H. Clinical trials of artemisinin and its derivatives in the treatment of malaria in China. Trans. R. Soc. Trop. Med. Hyg. 88(Suppl. 1):1994;5-6.
18. Li Q.G., Peggins J.O., Fleckenstein L.L., Masonic K., Heiffer M.H., Brewer T.G. The pharmacokinetics and bioavailability of dihydroartemisinin, arteether, artemether, artesunic acid and artelinic acid in rats. J. Pharm. Pharmacol. 50:1998;173-182.
19. Li Q.G., Brueckner R.P., Peggins J.O., Trotman K.M., Brewer T.G. Arteether toxicokinetics and pharmacokinetics in rats after 25 mg/kg/day single and multiple doses. Eur. J. Drug Metab. Pharmacokinet. 24:1999;213-223.
20. Li Q.G., Mog S.R., Si Y.Z., Kyle D.E., Gettayacamin M., Milhouse W.K. Neurotoxicity and efficacy of arteether related to its exposure times and exposure levels in rodents. Am. J. Trop. Med. Hyg. 66:2002;516-525.
21. Looareesuwan S. Overview of clinical studies on artemisinin derivatives in Thailand. Trans. R. Soc. Trop. Med. Hyg. 88(Suppl. 1):1994;9-11.
22. Magueur G., Crousse B., Ourevitch M., Begue J.P., Bonnet-Delpon D. Preparation of 10-trifluoromethyl artemether and artesunate. Influence of hexafluoropropan-2-ol on substitution reaction. J. Org. Chem. 68:2003;9763-9766.
23. Meshnick S.R., Taylor T.E., Kamchonwongpaisan S. Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol. Rev. 60:1996;301-315.
24. Miller L.G., Panosian C.B. Ataxia and slurred speech after artesunate treatment for falciparum malaria. N. Engl. J. Med. 336:1997;1328.
25. Navaratnam V., Mansor S.M., Sit N.W., Grace J., Li Q., Olliaro P. Pharmacokinetics of artemisinin-type compounds. Clin. Pharmacokinet. 39:2000;255-270.
26. Nontprasert A., Pukrittayakamee S., Nosten-Bertrand M., Vanijanonta S., White N.J. Studies of the neurotoxicity of oral artemisinin derivatives in mice. Am. J. Trop. Med. Hyg. 62:2000;409-412.
27. Nontprasert A., Pukrittayakamee S., Prakongpan S., Supanaranond W., Looareesuwan S., White N.J. Assessment of the neurotoxicity of oral dihydroartemisinin in mice. Trans. R. Soc. Trop. Med. Hyg. 96:2002;99-101.
28. Park B.K., O'Neill P.M., Maggs J.L., Pirmohamed M. Safety assessment of peroxide antimalarials: clinical and chemical perspectives. Br. J. Clin. Pharmacol. 46:1998;521-529.
29. Petras J.M., Young G.D., Bauman R.A., Kyle D.E., Gettayacamin M., Webster H.K., Corcoran K.D., Peggins J.O., Vane M.A., Brewer T.G. Arteether-induced brain injury in Macaca mulatta. I. The precerebellar nuclei: the lateral reticular nuclei, paramedian reticula nuclei, and perihypoglossal nuclei. Anat. Embryol. 20:2000;383-397.
30. Price R., van Vugt M., Phaipun L., Luxemburger C., Simpson J., McGready R., Ter Kuile F., Kham A., Chongsuphajaisiddhi T., White N.J., Nosten F. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am. J. Trop. Med. Hyg. 60:1999;547-555.
31. Price R. Artemisinin drugs: novel antimalarial agents. Expert Opin. Investig. Drugs. 9:2000;1815-1827.
32. Ribeiro I.R., Olliaro P. Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials. Med. Trop. (Mars.). 58(Suppl. 3):1998;50-53.
33. Rowland, M., Towzer, T.N., 1994. Clinical Pharmacokinetics: Concepts and Applications, third ed. Williams and Wilkins, Media, PA.
34. Teja-Isavadharm P., Nosten F., Kyle D.E., Luxemburger C., Ter Kuile F., Peggins J.O., Brewer T.G., White N.J. Comparative bioavailability of oral, rectal, and intramuscular artemether in healthy subjects: use of simultaneous measurement by high performance liquid chromatography and bioassay. Br. J. Clin. Pharmacol. 42:1996;599-604.
35. Titulaer H.A.C., Zuidema J., Kager P.A., Wetsteyn J.C.F.M., Lugt C.B., Merkus F.W.H.M. The pharmacokinetics of artemisinin after oral, intramuscular and rectal administration to volunteers. J. Pharm. Pharmacol. 42:1990;810-813.
36. Tran T.H., Day N.P., Nguyen H.P., Nguyen T.H., Tran T.H., Pham P.L., Dinh X.S., Ly V.C., Ha V., Waller D., Peto T.E., White N.J. A controlled trial of artemether or quinine in Vietnamese adults with sever falciparum-malaria. N. Engl. J. Med. 335:1996;76-83.
37. Valecha N., Gupta S., Usha D., Biswas S., Sharma A., Adak T., Asthana O.P., Sharma V.P. Efficacy of alpha, beta-arteether in acute uncomplicated P. falciparum malaria. Int. J. Clin. Pharmacol. Res. 17:1997;11-15.
38. Vanhensbroek M.B., Onyiorah E., Jaffar S., Scheneider G., Palmer A., Frenkel J., Enwere G., Forck S., Nusmeijer A., Bennett S., Greenwood B., Kwiatkowski D. A trial of artemether or quinine in children with cerebral malaria. N. Engl. J. Med. 335:1996;69-75.
39. Van Vugt M., Angus B.J., Price R.N., Mann C., Simpson J.A., Poletto C., Htoo S.E., Looareesuwan S., White N.J., Nosten F. A case-control auditory evaluation of patients treated with artemisinin derivatives for multidrug-resistant Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 62:2000;65-69.
40. Wesche D.L., DeCoster M.A., Tortella F.C., Brewer T.G. Neurotoxicity of artemisinin analogs in vitro. Antimicrob. Agent Chemother. 38:1994;1813-1819.
41. White N.J. Neurological dysfunction following malaria: disease- or drug-related? Clin. Infect. Dis. 30:2000;836.
42. Wong J.W., Yuen K.H. Improved oral bioavailability of artemisinin through inclusion complexation with beta- and gamma-cyclodextrins. Int. J. Pharm. 227:2001;177-185.